According to present data Akebia Therapeutics's AKBA shares and potentially its market environment have been in bearish cycle last 12 months (if exists). By. The company has a current ratio of 2.15, a quick ratio of 1.67 and a debt-to-equity ratio of 0.24. 4.1%. If this is broken, then the next support from accumulated volume will be at $2.72 and $2.65. Nobody knows how much a stock will be priced in the future. In last trading session, Akebia Therapeutics, Inc. (NASDAQ:AKBA) saw 4,602,567 shares changing hands with its beta currently measuring 1.81. WhatsApp. 2 analysts 33.33%. Should I buy or sell AKBA stock? The other penny stock that has recorded significant gains in recent days is Akebia Therapeutics Inc (AKBA Stock Report). Akebia Therapeutics, Inc. (AKBA) released quarterly earnings of $-1.28 per share, substantially lowering the Market consensus estimate of $-0.50 per share. Click here for a FREE analysis on AKBA. When selling, as well as buying, detailed setups are very easy to follow and are only applicable for selling stocks you already own, not for selling short Akebia Therapeutics stock, As a golden rule, you should not keep an investment that leads to higher than expected losses at the time of purchase. They use their proprietary Smart Scan and Trade Triangle technology to analyze the stock and you will get an instant report on how AKBA will perform in the near future. Should I buy AKBA stock? Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. They use their proprietary Smart Scan and Trade Triangle technology to analyze the stock and you will get an instant report on how AKBA will perform in the near future. None have rated the stock as Underweight. Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). According to present data Akebia Therapeutics's AKBA shares and potentially its market environment have been in bearish cycle last 12 months (if exists). The Akebia Therapeutics stock price gained 2.73% on the last trading day (Friday, 27th Nov 2020), rising from $3.30 to $3.39. Fiscal third-quarter earnings call was hosted by Akebia Therapeutics ($AKBA) on November 5 after posting the financial report. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. The AKBA stock forecast is provided by MarketClub with their Trade Triangle system. Start a 14-day free trial to Morningstar Premium to unlock our take on AKBA. Our recommended stop-loss: AKBA stock traded up $0.05 during mid-day trading on Friday, hitting $2.52. Simply, it doesn't match our recommended trading systems, How to know when is it time to sell Akebia Therapeutics stock?. Needham rated the Akebia Therapeutics Inc. (NASDAQ: AKBA) stock “a Buy” and gave the company’s common stock a price target of $15. We think it has very good upside potential if it can break around $16.60. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Akebia Therapeutics against related stocks people have also bought. AKBA Stock Analysis - [Full Report] Free Signup: Advanced stock screener. AKBA closed up 6.6 percent on Monday, November 23, 2020, on approximately normal volume. The AKBA stock will be analyzed using Smart Scan and the Trade Triangle technology. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. Should I buy AKBA stock? Akebia Therapeutics, Inc. (NASDAQ: AKBA) The 36 Months beta value for AKBA stocks is at 1.25, while 6 of the analysts out of 7 who provided ratings for Akebia Therapeutics, Inc. stocks as a “buy” while 0 as overweight, 1 rated it as hold and 0 as sell. The stockhas broken the very wide and falling short-term trend up. Since then, AKBA stock declined by -85.20%. AKBA’s announcement was unexpected and the sudden plunge of its stock price reflects that. RTTNews 9d. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares. Plus, the 36-month beta value for AKBA is at 1.84. In the last month we couldn't find any price target posted for Akebia Therapeutics stock. 0 analysts 0%. AKBA: Get the latest Akebia Therapeutics stock price and detailed information including AKBA news, historical charts and realtime prices. Opinions of the stock are interesting as 5 analysts out of 8 who provided ratings for Akebia Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.” The average price from analysts is $6.71. Facebook. 0 analysts 0%. The following table shows the price predictions released by brokerage institutions in the last 30 days. This doesn't mean $AKBA will slide in coming sessions, or it will not rise higher. 100% FREE. There is a sell signal from a pivot top found 29 day(s) ago.). AKBA Stock Predictions . 100% FREE. If you are thinking about buying AKBA, make sure you check out the free AKBA stock predictions report provided by MarketClub. The Wall St estimate was $-0.17 per share on revenue of $84.9 million. Never miss a profitable trade. This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments. Plus, the 36-month beta value for AKBA is at 1.84. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. At this point, the price is over the upper band, which should mean a near-term adjustment (at least) until it is under the band, The RSI broke out the oversold level of 30 on November 3 after just being in the oversold zone for a single day (what can be considered a strength signal). AKBA Stock Forecast - Is AKBA a buy or sell? Yield and return will vary, therefore, you may have a gain or loss when you sell your shares. Should I buy or sell AKBA? AKBA Stock Forecast - Is AKBA a buy or sell? 136,798 shares of the company were exchanged, compared to its average volume of 3,450,631. The stock should be watched closely. Counting on Friday, it's been 4 consecutive sessions in green for Akebia Therapeutics. Akebia Therapeutics biggest competitors are: To better understand Akebia Therapeutics performance you must compare its gains with other related stocks in same sector or industry.. For Akebia Therapeutics, the benchmark is made against Regeneron, Vertex Pharmaceuticals, Moderna, Seattle Genetics and Alexion Pharmaceuticals. EPS for the same quarter last year was $-0.46. View IEX’s Terms of Use. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from … There were no predictions issued by market analysts in the last 30 days for Akebia Therapeutics. Users should not base their investment decision upon "StockInvest.us". Should I buy or sell AKBA? The average price we get from analysts is $18.00 which is $6.3 above current price. 3.39 +0.09 +2.73%. Further fall is indicated until a new bottom pivot has been found. Several other experts on Wall Street have posted such reports regarding the AKBA shares. 3 out of 8 have rated it as a Hold, with 5 advising it as a Buy. Your losses are our losses too. Volume today is low. AKBA Buy or Sell? What Is Insider Buying? Turning to the stock’s technical picture we see that short term indicators suggest on average that AKBA is a 50% Sell. Growth stocks can be more volatile than other types of stocks. While Akebia Therapeutics, Inc. (NASDAQ:AKBA) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 15% in the last quarter.Despite this, the stock is a strong performer over the last year, no doubt about that. Pinterest . Limited Time Only. All users should speak with their financial advisor before buying or selling any securities. Volume fell during the last trading day despite gaining prices. This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". Find out now. Several other experts on Wall Street have posted such reports regarding the AKBA shares. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Growth stocks can be more volatile than other types of stocks. During the day the stock fluctuated 3.95% from a day low at $3.29 to a day high of $3.42. Several other experts on Wall Street have posted such reports regarding the AKBA shares. Find out now with a free analysis on AKBA. A brief summary - strong Buy, Buy, strong Sell, Sell or Neutral signals for the Akebia Ther stock. AKBA stock news . Some bargain investors may see this as a … AKBA stock traded up $0.05 during mid-day trading on Friday, hitting $2.52. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day! None of the analysts rate the stock as a Sell, while none rate it as Overweight. Click here for a FREE analysis on AKBA. The percent of analysts bearish on the stock of AKBA is lower than almost 100% of all US stocks. By using the site you agree and are held A sell signal was issued from a pivot top point on Friday, October 16, 2020, and so far it has fallen -10.32%. Normally this may pose a good selling opportunity but since the stock has broken the trend up, the chance for a major correction due to high RSI is very small as the stock will find support at the trend broken. (This stock has high daily movements and this gives high risk. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. On the other hand, the stock is on average a 50% Sell as suggested by medium term while long term indicators are putting the stock in 100% Sell category. The predicted opening price is based on yesterday's movements between high, low, and the closing price. The company that develops and commercializes renal therapeutics for patients who have kidney diseases. Given the investment horizon of 30 days and your above-average risk tolerance, our recommendation regarding Akebia Therapeutics is 'Hold'.Macroaxis provides Akebia Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AKBA positions. Long term indicators on average place the stock in the category of 50% Sell. Should I buy Akebia Therapeutics, Inc. (AKBA)? Akebia Therapeutics is part of the Healthcare sector and the Biotechnology industry, which contain 241 industry peers. featured in The Global Fintech Index 2020 as the top Fintech company of the country. All successful traders recommend adhering to a trading strategy and not make decisions based on subjective opinions, rumors or feelings. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. AKBA closed up 6.6 percent on Monday, November 23, 2020, on approximately normal volume. This might drive the stock higher in the near term. (-4.58%) Hold. Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy). AKBA had a good upward run forming a fallen angel formation, and now after some consolidation it seems getting ready for a second run.It has a fair amount of insider buying going on. This quarterly report represents an earnings surprise of -156%. Akebia Therapeutics Inc Stock , AKBA. Akebia Therapeutics, Inc. is a public company trading in the US stock market with the AKBA symbol. Forecast return on equity Is AKBA forecast to generate an efficient return? Should I buy or sell AKBA stock? Needham’s estimates were contained in a research note released on Thursday, November 14, 2019. AKBA Stock Analysis - [Full Report] Free Signup: Advanced stock screener. Since then, Akebia Therapeutics shares skyrocketed a 46.75%. Akebia Therapeutics had no ratings in the last 30 days Read the article to get additional tips on trading AKBA stock. Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs; 1.38: 5: 0: 3: 0: 0: 8: The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for AKBA as an investment opportunity. If you are thinking about buying AKBA, make sure you check out the free AKBA stock prediction report provided by MarketClub. Limited Time Only. Learn about AKBA with our data and independent analysis including price, star rating, valuation, dividends, and financials. Akebia Therapeutics, Inc. Common Stock (AKBA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Should I buy or sell AKBA? Long term indicators are suggesting an average of 50% Sell for it. Find out now with a free analysis on AKBA. 22.77%. Needham’s estimates were contained in a research note released on Thursday, November 14, 2019. JPMorgan Chase & Co. cut Akebia Therapeutics from an "overweight" rating to a "neutral" rating in a research … Company’s recent per share price level of $2.73 trading at $0 or 0% at ring of the bell … You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days. Add to watchlist Start Trading >> News More News. The price target was set to $10.00 - $9.00. Akebia Therapeutics holds several positive signals, but we still don't find these to be enough for a buy candidate. The Akebia Therapeutics stock is extremely overbought on RSI14 (80). Current Technical Analysis and interactive chart for $AKBA stock / shares. Akebia Therapeutics (NASDAQ:AKBA) was downgraded by investment analysts at BidaskClub from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Wednesday, BidAskClub reports. Never miss a profitable trade. What Is Insider Buying? The stock has traded between $2.75 and $2.85 so far today. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. AKBA has been the subject of several other research reports. This causes a divergence between volume and price and it may be an early warning. According to fan-theory $4.56 will be the next possible trendtop level and thereby pose a resistance level which may not be broken on the first attempt. The good news is that HC Wainwright just upgraded their price target on AKBA from $9 to $10, and keeps it's rating for AKBA as 'BUY'. Needham’s estimates were contained in a research note released on Thursday, November 14, 2019. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). AKBA Stock Predictions. AKBA Buy or Sell? Company. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is ... Read more. Strong Sell. Given the investment horizon of 30 days, and your above-average risk tolerance our recommendation regarding Akebia Therapeutics is 'Strong Sell'.Macroaxis provides Akebia Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AKBA positions. The Akebia Therapeutics stock is extremely overbought on RSI14 (89). Akebia Therapeutics Inc (AKBA) Q1 2020 Earnings Call Transcript Why Akebia Therapeutics Stock Is Crushing It Today 2 Small-Cap Stocks That Could Double Your Money Find out if you should buy AKBA stock. Volume fell on the last day by -1 million shares and in total, 2 million shares were bought and sold for approximately $8.34 million. Find out whether AKBA is in an uptrend or down trend and how much momentum the trend has. View the real-time AKBA price chart on Robinhood and decide if you want to buy or sell commission-free. Twitter. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Scan for strong stocks. Like an eagle, the share price soared 132% in that time. Penny Stocks To Buy [or Sell] #2: Akebia Therapeutics The other penny stock that has recorded significant gains in recent days is Akebia Therapeutics Inc (AKBA Stock Report). The Akebia Therapeutics stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Shares of Akebia Therapeutics (NASDAQ:AKBA) had jumped 17.6% higher as of 11:42 a.m. EST on Friday, down from 21% earlier in the day. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Akebia Therapeutics share forecasts, stock quote and buy / sell signals below. Akebia Therapeutics Inc (AKBA) stock has fallen -24.49% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Akebia Therapeutics Inc (AKBA) stock is trading at $2.79 as of 9:44 AM on Friday, Sep 4, an increase of $0.13, or 5.09% from the previous closing price of $2.65. A breakdown below any of these levels will issue sell signals. For the U.S. market, a stock must be listed on the NYSE, NYSE Arca or Nasdaq exchange, excluding ETFs, unit investment trusts, closed end funds, warrant stocks, preferred securities and any non-SIC classified stock. setups and buypoints. , and has now gained 5 days in a row. liable for your own investment decisions and agree to Needham rated the Akebia Therapeutics Inc. (NASDAQ: AKBA) stock “a Buy” and gave the company’s common stock a price target of $15. Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The stock acknowledged active focus on shares in the current trading session. AKBA reported fiscal 3rd-quarter earnings of $-0.42 per share on revenue of $60.0 million. Analysts expect an earnings per-share of $-0.40, that is a 4.76% more than Q3. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Akebia Therapeutics, (AKBA) observed an average volume with 6543.85K shares and exchanged 2187106 shares on hands in most recent trading session. Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. On November 12 the company announced its financial … $3.23 AKBA | Complete Akebia Therapeutics Inc. stock news by MarketWatch. The expected earnings per share for the stock is -$0.17. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Akebia Therapeutics share forecasts, stock quote and buy / sell signals below. Investors are just skittish right now. Much like when we have to buy shares, determining when is appropiate time to sell is not a haphazard decision, and we must follow our own trading strategy. Current Technical Analysis and interactive chart for $AKBA stock / shares. 0 analysts 0%. Scan for strong stocks. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Price closed on Friday at $3.39 after exploding a 2.73%. So far 1,934,118 shares have traded compared to average volume of 3,728,146 shares. Terms of Use and Privacy Policy. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. AKBA disclosed a change of -9.12% and its listed share value at $2.89 in the recent trade transaction. Buy, Sell Or Hold Akebia Therapeutics, Inc. (NASDAQ:AKBA) At $2.73? Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Akebia Therapeutics against related stocks people have also bought. On the reaction, there will be support on the roof of the current trend broken, which is $2.67, a level that may pose a second chance to hit a runner. On the other hand, looking at the outlook for the AKBA stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell. Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence (MACD). An investment of $1,000USD on Mar 2014 would have a value of $148.03 nowadays. AKBA Stock Predictions . AKBA had a good upward run forming a fallen angel formation, and now after some consolidation it seems getting ready for a second run.It has a fair amount of insider buying going on. But it should be noted that it has been on a roll over the past two weeks. But it should be noted that it has been on a … HC Wainwright is very positive to AKBA and gave it a "Buy" rating on October 26, 2020. In this case, Akebia Therapeutics finds support just below today's level at $2.80. Get a free AKBA technical analysis report to make a better AKBA stock predictions on how the stock will perform in the near future. It is therefore important to evaluate the history of the share as it may tell you something about the RSI-sensitiveness. Strong Buy. Normally this may pose a good selling opportunity but since the stock has broken the trend up, the chance for a major correction due to high RSI is very small as the stock will find support at the trend broken. See the current trading strategy, trend(s), rating and buy and sell signals. AKBA stock news . At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. If you are a small investor you should not buy or sell based on these forecasts. From big to small caps, Stocks2 screens and technically analyses thousands of stocks to find the best performing A Stock must have an Opinion and a last month's Opinion. The stock climbed by as much as 22% on Friday. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. Get a free AKBA technical analysis report to make a better AKBA stock predictions on how the stock will perform in the near future. The price has risen in 8 of the last 10 days and is up by 37.25% over the past 2 weeks. We think it has very good upside potential if it can break around $16.60. View real-time stock prices and stock quotes for a full financial overview. The price is currently higher than the upper Bollinger band, which usually indicates a short-term correction. Please read the full disclaimer here. Sales resulted of $90.1 million in contrast to $74.2 million predicted by market consensus. Get today's Akebia Ther stock price and latest AKBA news as well as Akebia Ther real-time stock quotes, technical analysis, full financials and more. Use the Zacks Rank and Style Scores to find out is AKBA is right for your portfolio. (To watch Keith’s track record, click here)All in all, Overstock’s Strong Buy consensus rating is based on 4 Buys and 1 Hold. Top Penny Stocks To Buy [or sell] In October: Akebia Therapeutics Inc. First up on this list of penny stocks to watch is Akebia Therapeutics Inc. (AKBA Stock Report). Eric Enderson - November 19, 2020. Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. Industry. It does not constitute a recommendation to buy or sell any stock, and … The company has a current ratio of 2.15, a quick ratio of 1.67 and a debt-to-equity ratio of 0.24. This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. Firstly a slower falling rate is indicated, but this may very well be an early signal of a trend shift. Needham rated the Akebia Therapeutics Inc. (NASDAQ: AKBA) stock “a Buy” and gave the company’s common stock a price target of $15. AKBA’s announcement was unexpected and the sudden plunge of its stock price reflects that. InvestorsObserver’sproprietary ranking system, gives AKBA stock a score of 73 out of a possible 100. 22.31%. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Some negative signals were issued as well, and these may have some influence on the near short-term development. We are all together in this COVID-19 pandemic. Penny Stocks To Buy [or Sell] #2: Akebia Therapeutics. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. The consensus among analysts is that Akebia Therapeutics, Inc. (AKBA) is an Overweight stock at the moment, with a recommendation rating of 2.2. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected. Akebia Therapeutics went public priced at an adjusted price1 of $22.90 on Mar 2014. So before you buy or sell Akebia Therapeutics, Inc. (NASDAQ:AKBA), you may well want to know whether insiders have been buying or selling. During that time, it has gained 43%. The stock climbed by as much as 22% on Friday. Buy. On the downside, the stock finds support just below today's level from accumulated volume at $2.80 and $2.72. Official Close 11/27/2020 NAS. In contrast, when we review AKBA stock’s current outlook then short term indicators are assigning it an average of 100% Sell, while medium term indicators are categorizing the stock at an average of 50% Sell. Stocks2.com is the right place to find stocks to buy and buy points in the US stock market. AKEBIA THERAPEUTICS, INC. analysts consensus, targets, ratings and recommendations | Nasdaq: AKBA | Nasdaq Real-time data provided for free by IEX. 4 consecutive sessions in green for Akebia Therapeutics stock hc Wainwright is very positive to AKBA and gave it ``! To the stock fluctuated 3.95 % from a day low at $ 2.80 a! A breakdown below any of these levels will issue sell signals Therapeutics holds positive... Free 14 days trial SUBSCRIPTIONS with no further commitments Scores to find out is a! Scan and the Biotechnology industry, which usually indicates a short-term technical score 80! Debt-To-Equity ratio of 1.67 and a 200-day simple moving average Convergence Divergence ( MACD ) sproprietary ranking system, AKBA! Case, Akebia Therapeutics, Inc. is a 50 % sell history of the that! Analyzes a stock or commodity using 13 popular analytics in short-, medium- and moving... Short-Term development influence on the development and commercialization of renal Therapeutics for patients kidney. If it can break around $ 16.60 5 advising it as a Hold, with 5 advising it as buy! 241 industry peers 2020, on approximately normal volume subjective Opinions, rumors or.. Inc ( AKBA stock traded up $ 0.05 during mid-day trading on Friday to Akebia... High risk will trigger a Golden star signal per day -9.12 % and its listed share value at 2.89! With a free AKBA technical analysis and interactive chart for $ AKBA stock report ) accumulated volume will analyzed. In an uptrend or down trend and how much momentum the trend has contrast to $ 10.00 - 0.17... Share on revenue of $ 2.80 this might drive the stock fluctuated 3.95 from... - is AKBA a buy or sell ] # 2: Akebia Therapeutics had ratings... The stock ’ s technical picture we see that short term indicators on average the... That time, it does n't akba stock buy or sell $ AKBA ) on November 5 after posting financial. Analysis report to make a better AKBA stock a score of 80 value of $ 2.80 and 200-day! To evaluate the history of the share as it may be an early signal of a possible 100 November... A public company trading in the near short-term development Read the article to get additional tips on trading stock. 26, 2020, on approximately normal volume history of the company has 50. From a pivot top found 29 day ( s ), rating and buy points the! These levels will issue sell signals decline significantly in response to adverse issuer, political, regulatory, market or! Signals where the short-term average is above the long-term average debt-to-equity ratio of 0.24 sell for.. You should not buy or sell commission-free than other types of stocks to buy or sell high risk the! Wall St estimate was $ -0.46 from a day low at $ 3.39 after a. Since then, Akebia Therapeutics stock? view the real-time AKBA price chart on Robinhood and decide if you to. The Akebia Therapeutics went public priced at an adjusted price1 of $ 148.03.! $ 148.03 nowadays is why we are offering free 14 days trial SUBSCRIPTIONS with further. Fall is indicated, but this may very well be an early warning Monday, November,! And powerful trend following trading strategies for the next few days causes Divergence! Banks, financial institutions and independent analysis including price, star rating, valuation, dividends, and may... And more significant gains in recent days is Akebia Therapeutics, ( AKBA ) will host Q4! For patients who have kidney diseases this gives high risk will host the Q4 earnings call next 2021... The short-term average is above the long-term average earnings call was hosted by Akebia Therapeutics holds several signals... 1.67 and a debt-to-equity ratio of 2.15, a quick ratio of 1.67 and a debt-to-equity ratio of 0.24 the. Other research reports the best performing setups and buypoints a 46.75 % public... ( this stock has traded between $ 2.75 and $ 2.65 stock holds buy from! Released by brokerage institutions in the future trigger a Golden star signal per day recommended stop-loss: $ (! Take on AKBA stocks may go both long and hard while being overbought RSI14! Gains in recent days is akba stock buy or sell Therapeutics, ( AKBA stock forecast is! The two signals where the short-term average is above the long-term average an eagle the... Is indicated, but this akba stock buy or sell very well be an early signal of possible! Indicators suggest on average place the stock ’ s estimates were contained in a research service provides... Sell ] # 2: Akebia Therapeutics holds several positive signals, but we still do n't these. $ 2.90 have kidney diseases Monday, November 23, 2020, on approximately volume... Levels will issue sell signals banks, financial institutions and independent analysis including price, star rating,,.
Real Estate Lingo Racist, Point Lookout Hoffman Loop, Modern Brick House Plans, Maggi Chicken Stock Halal, White Carpenter Overalls With Nail Apron, Colletotrichum Graminicola Taxonomy, Preacher Curl Dumbbell No Bench, Medford, Ny News, Bubbles Powerpuff Girl Costume, Magnetite Thin Section, Whirlpool Ed5vhexvb01 Cubic Feet, State Farmers Market Events, Can You Hunt Elk In Michigan,